- Home
- HEPA vs TCRT Comparison
HEPA vs TCRT Comparison
Compare HEPA & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPA
- TCRT
- Stock Information
- Founded
- HEPA 2013
- TCRT 1998
- Country
- HEPA United States
- TCRT United States
- Employees
- HEPA N/A
- TCRT N/A
- Industry
- HEPA Biotechnology: Pharmaceutical Preparations
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- HEPA Health Care
- TCRT Health Care
- Exchange
- HEPA Nasdaq
- TCRT Nasdaq
- Market Cap
- HEPA 4.1M
- TCRT 3.8M
- IPO Year
- HEPA N/A
- TCRT N/A
- Fundamental
- Price
- HEPA $0.57
- TCRT $2.00
- Analyst Decision
- HEPA Hold
- TCRT
- Analyst Count
- HEPA 1
- TCRT 0
- Target Price
- HEPA N/A
- TCRT N/A
- AVG Volume (30 Days)
- HEPA 27.9K
- TCRT 33.8K
- Earning Date
- HEPA 11-14-2024
- TCRT 11-14-2024
- Dividend Yield
- HEPA N/A
- TCRT N/A
- EPS Growth
- HEPA N/A
- TCRT N/A
- EPS
- HEPA N/A
- TCRT N/A
- Revenue
- HEPA N/A
- TCRT $7,000.00
- Revenue This Year
- HEPA N/A
- TCRT N/A
- Revenue Next Year
- HEPA N/A
- TCRT N/A
- P/E Ratio
- HEPA N/A
- TCRT N/A
- Revenue Growth
- HEPA N/A
- TCRT N/A
- 52 Week Low
- HEPA $0.48
- TCRT $1.63
- 52 Week High
- HEPA $3.72
- TCRT $33.00
- Technical
- Relative Strength Index (RSI)
- HEPA 39.66
- TCRT 45.33
- Support Level
- HEPA $0.48
- TCRT $1.63
- Resistance Level
- HEPA $0.66
- TCRT $2.10
- Average True Range (ATR)
- HEPA 0.06
- TCRT 0.31
- MACD
- HEPA -0.01
- TCRT -0.04
- Stochastic Oscillator
- HEPA 32.88
- TCRT 25.17
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.